Offerings	Mar. 26, 2026 USD ($) shares
Offering: 1
Offering:
Fee Previously Paid	false
Other Rule	true
Security Type	Equity
Security Class Title	Ordinary shares, nominal value GBP0.002 per share
Amount Registered \| shares	7,461,403
Proposed Maximum Offering Price per Unit	29.10
Maximum Aggregate Offering Price	$ 217,126,827.30
Fee Rate	0.01381%
Amount of Registration Fee	$ 29,985.21
Offering Note	These shares may be represented by the American Depositary Shares ("ADSs") of Centessa Pharmaceuticals plc ("the Registrant"). Each ADS represents one Ordinary Share, nominal value GBP0.002 per share. ADSs issuable upon deposit of the Ordinary Shares registered hereby were registered pursuant to a separate Registration Statement on Form F-6 (File No. 333-256385). Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Security Act"), this Registration Statement shall also cover any additional Ordinary Shares of the Registrant which become issuable under the above-named plans by reason of any stock dividend, stock split, recapitalization, anti-dilution or any other similar transaction effected without the receipt of consideration which results in an increase in the number of the Registrant's outstanding Ordinary Shares. Pursuant to Rule 416(c) under the Securities Act, this Registration Statement shall also cover an indeterminate amount of interests to be offered or sold pursuant to the employee benefit plans described herein. In accordance with Rule 457(h)(2), no separate fee calculation is made for plan interests. The "Amount Registered" represents an automatic increase to the number of Ordinary Shares available for issuance under the Registrant's 2021 Share Option and Incentive Plan (the "2021 Plan") effective as of January 1, 2026. Ordinary Shares available for issuance under the 2021 Plan were previously registered on Form S-8 filed with the Securities and Exchange Commission on June 11, 2021 (Registration No. 333-257027), July 1, 2022 (Registration No. 333-265977), March 30, 2023 (File No. 333-270968), March 28, 2024 (File No. 333-278341) and March 24, 2025 (File No. 333-286048). "Proposed Maximum Offering Price Per Share" and "Maximum Aggregate Offering Price" are estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and (h)(1) of the Securities Act, and based on the average of the high and low sale prices of the Registrant's ADSs as reported on the Nasdaq Global Select Market on March 26, 2026.
Offering: 2
Offering:
Fee Previously Paid	false
Other Rule	true
Security Type	Equity
Security Class Title	Ordinary shares, nominal value GBP0.002 per share
Amount Registered \| shares	100
Proposed Maximum Offering Price per Unit	29.10
Maximum Aggregate Offering Price	$ 2,910.00
Fee Rate	0.01381%
Amount of Registration Fee	$ 0.40
Offering Note	These shares may be represented by the American Depositary Shares ("ADSs") of Centessa Pharmaceuticals plc ("the Registrant"). Each ADS represents one Ordinary Share, nominal value GBP0.002 per share. ADSs issuable upon deposit of the Ordinary Shares registered hereby were registered pursuant to a separate Registration Statement on Form F-6 (File No. 333-256385). Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Security Act"), this Registration Statement shall also cover any additional Ordinary Shares of the Registrant which become issuable under the above-named plans by reason of any stock dividend, stock split, recapitalization, anti-dilution or any other similar transaction effected without the receipt of consideration which results in an increase in the number of the Registrant's outstanding Ordinary Shares. Pursuant to Rule 416(c) under the Securities Act, this Registration Statement shall also cover an indeterminate amount of interests to be offered or sold pursuant to the employee benefit plans described herein. In accordance with Rule 457(h)(2), no separate fee calculation is made for plan interests. The "Amount Registered" represents an automatic increase to the number of shares available for issuance under the Registrant's 2021 Employee Share Purchase Plan (the "2021 ESPP") effective as of January 1, 2026. Shares available for issuance under the 2021 ESPP were previously registered on Form S-8 filed with the Securities and Exchange Commission on June 11, 2021 (Registration No. 333-257027), July 1, 2022 (Registration No. 333-265977), March 30, 2023 (File No. 333-270968), March 28, 2024 (File No. 333-278341) and March 24, 2025 (File No. 333-286048). "Proposed Maximum Offering Price Per Share" and "Maximum Aggregate Offering Price" are estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and (h)(1) of the Securities Act, and based on the average of the high and low sale prices of the Registrant's ADSs as reported on the Nasdaq Global Select Market on March 26, 2026.

Offerings

Mar. 26, 2026

USD ($)

Offering:

false

true

Equity

Ordinary shares, nominal value GBP0.002 per share

Amount Registered | shares

7,461,403

Proposed Maximum Offering Price per Unit

29.10

Maximum Aggregate Offering Price

$ 217,126,827.30

Fee Rate

0.01381%

Amount of Registration Fee

$ 29,985.21

Offering Note

These shares may be represented by the American Depositary Shares ("ADSs") of Centessa Pharmaceuticals plc ("the Registrant"). Each ADS represents one Ordinary Share, nominal value GBP0.002 per share. ADSs issuable upon deposit of the Ordinary Shares registered hereby were registered pursuant to a separate Registration Statement on Form F-6 (File No. 333-256385). Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Security Act"), this Registration Statement shall also cover any additional Ordinary Shares of the Registrant which become issuable under the above-named plans by reason of any stock dividend, stock split, recapitalization, anti-dilution or any other similar transaction effected without the receipt of consideration which results in an increase in the number of the Registrant's outstanding Ordinary Shares. Pursuant to Rule 416(c) under the Securities Act, this Registration Statement shall also cover an indeterminate amount of interests to be offered or sold pursuant to the employee benefit plans described herein. In accordance with Rule 457(h)(2), no separate fee calculation is made for plan interests. The "Amount Registered" represents an automatic increase to the number of Ordinary Shares available for issuance under the Registrant's 2021 Share Option and Incentive Plan (the "2021 Plan") effective as of January 1, 2026. Ordinary Shares available for issuance under the 2021 Plan were previously registered on Form S-8 filed with the Securities and Exchange Commission on June 11, 2021 (Registration No. 333-257027), July 1, 2022 (Registration No. 333-265977), March 30, 2023 (File No. 333-270968), March 28, 2024 (File No. 333-278341) and March 24, 2025 (File No. 333-286048). "Proposed Maximum Offering Price Per Share" and "Maximum Aggregate Offering Price" are estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and (h)(1) of the Securities Act, and based on the average of the high and low sale prices of the Registrant's ADSs as reported on the Nasdaq Global Select Market on March 26, 2026.

Offering:

false

true

Equity

Ordinary shares, nominal value GBP0.002 per share

Amount Registered | shares

100

Proposed Maximum Offering Price per Unit

29.10

Maximum Aggregate Offering Price

$ 2,910.00

Fee Rate

0.01381%

Amount of Registration Fee

$ 0.40

Offering Note

These shares may be represented by the American Depositary Shares ("ADSs") of Centessa Pharmaceuticals plc ("the Registrant"). Each ADS represents one Ordinary Share, nominal value GBP0.002 per share. ADSs issuable upon deposit of the Ordinary Shares registered hereby were registered pursuant to a separate Registration Statement on Form F-6 (File No. 333-256385). Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Security Act"), this Registration Statement shall also cover any additional Ordinary Shares of the Registrant which become issuable under the above-named plans by reason of any stock dividend, stock split, recapitalization, anti-dilution or any other similar transaction effected without the receipt of consideration which results in an increase in the number of the Registrant's outstanding Ordinary Shares. Pursuant to Rule 416(c) under the Securities Act, this Registration Statement shall also cover an indeterminate amount of interests to be offered or sold pursuant to the employee benefit plans described herein. In accordance with Rule 457(h)(2), no separate fee calculation is made for plan interests. The "Amount Registered" represents an automatic increase to the number of shares available for issuance under the Registrant's 2021 Employee Share Purchase Plan (the "2021 ESPP") effective as of January 1, 2026. Shares available for issuance under the 2021 ESPP were previously registered on Form S-8 filed with the Securities and Exchange Commission on June 11, 2021 (Registration No. 333-257027), July 1, 2022 (Registration No. 333-265977), March 30, 2023 (File No. 333-270968), March 28, 2024 (File No. 333-278341) and March 24, 2025 (File No. 333-286048). "Proposed Maximum Offering Price Per Share" and "Maximum Aggregate Offering Price" are estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and (h)(1) of the Securities Act, and based on the average of the high and low sale prices of the Registrant's ADSs as reported on the Nasdaq Global Select Market on March 26, 2026.